Severe Asthma Treatment Market Envisages a Promising US$ 36.18 Billion Valuation in 2033-FMI Study

Severe Asthma Treatment Market

According to Future Market Insights, the global Severe Asthma Treatment Market sales will expand at a 5.1% CAGR from 2023 to 2033, reaching US$ 36.18 billion by 2033. Severe Asthma Treatment has undergone a huge shift with the emergence of biologics and customised treatments, offering hope to millions of individuals worldwide who suffer from the disease.

Biologics, which are made from living organisms, have emerged as a promising development in the treatment of severe asthma by targeting specific immune system pathways that cause inflammation in the airways. In clinical trials, these medications shown remarkable efficacy and are increasingly being used to treat severe asthma patients who do not respond well to standard therapy.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16760

Some of the most commonly used biologics for severe asthma treatment are omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. These medications have been found to improve lung function, reduce asthma exacerbations, and improve overall quality of life in severe asthma patients when administered subcutaneously or intravenously.

The global Severe Asthma Treatment market is predicted to develop in the future years as more people are diagnosed with severe asthma and more breakthrough medications become available.

Key Takeaways:

• The market for Severe Asthma Treatment is expected to increase at a 5.1% CAGR between 2023 and 2033.
• In 2023, it is expected that the inhaled route of administration would account for 40% of the severe asthma therapy market.
• North America is expected to retain 45% of the market for severe asthma therapy in 2023.
• Europe’s market for Severe Asthma Treatment is expected to account for 39% of the total by 2023.

“Advancements in treatments along with innovation of treatment options is expected to favor the growth of the market in the upcoming years.” states an FMI analyst

Competitive Landscape

Key players in the Severe Asthma Treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion

• GlaxoSmithKline’s discovery and marketing of a biologic drug called Nucala has been one of the company’s most significant breakthroughs in the treatment of severe asthma (mepolizumab). Nucala is an anti-IL-5 monoclonal antibody that is used to treat severe eosinophilic asthma, which is characterised by high eosinophil levels in the blood and airways.
• Novartis’ most major contribution to the treatment of severe asthma (omalizumab) has been the development and commercialization of a biologic medication called Xolair. Xolair is a monoclonal anti-IgE antibody that is used to treat severe allergic asthma caused by allergens such as pollen, dust mites, and animal dander.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Severe Asthma Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16760

Key Segments:

Drug Class:

• Reslizumab
• Benralizumab
• Anti-inflammatory

Route of Administration:

• Oral
• Inhaled
• Intravenous
• Subcutaneous

Device Type:

• Dry powder inhalers
• Metered dose inhalers
• Soft mist inhalers

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube